Eli Lilly and (NYSE:LLY) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided EPS guidance of 7.800-8.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.230. The company issued revenue guidance of $26.60 billion-$27.60 billion, compared to the consensus revenue estimate of $27.69 billion.
LLY opened at $187.04 on Tuesday. Eli Lilly and has a one year low of $129.21 and a one year high of $218.00. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. The company’s 50 day simple moving average is $185.84 and its 200-day simple moving average is $176.06. The stock has a market capitalization of $179.37 billion, a P/E ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Monday, April 26th. The company reported $1.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.12 by ($0.25). The business had revenue of $6.81 billion during the quarter, compared to analyst estimates of $7.10 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.75 earnings per share. As a group, analysts anticipate that Eli Lilly and will post 7.56 EPS for the current year.
Several brokerages have recently issued reports on LLY. Cowen increased their price objective on shares of Eli Lilly and from $195.00 to $235.00 and gave the stock an outperform rating in a research report on Friday, February 12th. Truist Securities raised their target price on shares of Eli Lilly and from $215.00 to $225.00 and gave the company a buy rating in a research report on Monday, March 22nd. Mizuho decreased their target price on shares of Eli Lilly and from $228.00 to $216.00 and set a buy rating for the company in a research report on Tuesday. Morgan Stanley decreased their price objective on shares of Eli Lilly and from $217.00 to $207.00 and set an overweight rating for the company in a research report on Tuesday. Finally, Bank of America lifted their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a buy rating in a research note on Friday, January 22nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $200.75.
In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of Eli Lilly and stock in a transaction on Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the completion of the sale, the insider now owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 3,000 shares of Eli Lilly and stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $181.38, for a total transaction of $544,140.00. Following the completion of the sale, the chief accounting officer now directly owns 5,987 shares of the company’s stock, valued at approximately $1,085,922.06. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Article: Golden Cross
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.